{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T09:07:31Z","timestamp":1779959251817,"version":"3.53.1"},"reference-count":41,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Psoriasis is a chronic immune-mediated inflammatory disease characterized by heterogeneous clinical presentation and variable response to biologic therapy. Genetic variation within the IL-23\/Th17 inflammatory pathway may influence treatment outcomes. This study evaluated the association between IL12B rs3213094 and IL23R rs11209026 single-nucleotide polymorphisms (SNPs) and response to biologic therapy in patients with moderate-to-severe psoriasis. Materials and Methods: We conducted a multicenter observational study including 92 Romanian patients with moderate-to-severe psoriasis vulgaris receiving their first biologic therapy (anti-TNF, anti-IL-17, or anti-IL-23 monoclonal antibodies). Clinical response was assessed using the Psoriasis Area and Severity Index (PASI) at baseline and weeks 12, 24, 36, and 48. Early response was defined as achieving PASI75 at week 12. Patient-reported disease impact was assessed using the Dermatology Life Quality Index (DLQI) at the same time points. Genotyping of IL12B rs3213094 and IL23R rs11209026 was performed using TaqMan assays. Longitudinal PASI dynamics were analyzed using repeated-measures ANOVA, while multivariable logistic regression was used to identify independent predictors of PASI75 at week 12. Results: A significant reduction in PASI scores over time was observed (p &lt; 0.001). The IL12B rs3213094 genotype was associated with differences in early response kinetics, with T-allele carriers showing significantly greater PASI improvement at week 12 compared with CC homozygotes (90.0% vs. 65.7%, p = 0.003). This effect was limited to early treatment and attenuated at later time points. In multivariable analysis, the IL12B rs3213094 CT + TT genotype was independently associated with PASI75 achievement at week 12 (OR = 4.285, 95% CI 1.500\u201312.239, p = 0.007). Treatment with anti-IL-17 agents was also an independent predictor of early response (OR = 3.946, 95% CI 1.416\u201310.998, p = 0.009). No significant association was observed between IL23R rs11209026 and treatment response. DLQI scores improved significantly over time (p &lt; 0.001), without genotype-dependent differences. Conclusions: IL12B rs3213094 SNP is significantly associated with early biologic treatment response in psoriasis, supporting its potential role as a pharmacogenetic biomarker of treatment responsiveness. These findings may inform the integration of genetic markers into personalized therapeutic strategies, particularly in underrepresented populations such as those from Eastern Europe. Further studies in larger cohorts are warranted to validate these results.<\/jats:p>","DOI":"10.3390\/medicina62061041","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:00:36Z","timestamp":1779955236000},"page":"1041","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IL12B rs3213094 as a Predictor of Early Response to Biologic Therapy in Psoriasis: A Real-World Study in a Romanian Cohort"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6273-0787","authenticated-orcid":false,"given":"Alessandra-Madalina","family":"Matei-Man","sequence":"first","affiliation":[{"name":"Dermatology Department, Faculty of Medicine, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy, 400126 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4726-915X","authenticated-orcid":false,"given":"Ildiko-Orsolya","family":"Gaal","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy, Pasteur Street 6, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9340-348X","authenticated-orcid":false,"given":"Andreea","family":"Catana","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy, Pasteur Street 6, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4549-3526","authenticated-orcid":false,"given":"Stefan","family":"Vesa","sequence":"additional","affiliation":[{"name":"Department 2 Functional Sciences, Discipline of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Senila","sequence":"additional","affiliation":[{"name":"Dermatology Department, Faculty of Medicine, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy, 400126 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeta","family":"Candrea","sequence":"additional","affiliation":[{"name":"Dermatology Department, Faculty of Medicine, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy, 400126 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meda","family":"Orasan","sequence":"additional","affiliation":[{"name":"Physiopathology Department, Faculty of Medicine, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy, 400126 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8817-3914","authenticated-orcid":false,"given":"Alexandra","family":"Puskas","sequence":"additional","affiliation":[{"name":"Independent Researcher, 1021 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Calina","family":"Man","sequence":"additional","affiliation":[{"name":"Life Sciences, Biotechnology Department, Harvard Extension School, Cambridge, MA 02138, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Mocan","sequence":"additional","affiliation":[{"name":"Physiology Department, Faculty of Medicine, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy, 400126 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Eisen, M., Hartmane, I., Kingo, K., Mikazans, I., Toomson, T., Toomela, K., and Valiukeviciene, S. (2025). The Real-World Burden of Moderate-to-Severe Psoriasis in Patients Under Systemic Treatment from Baltic Countries: Data from the CRYSTAL Observational Study. Medicina, 61.","DOI":"10.3390\/medicina61030397"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/1346-8138.15840","article-title":"Psoriasis: Comorbidities","volume":"48","author":"Yamazaki","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/ijd.17848","article-title":"Epidemiology of Psoriasis in Poland: Prevalence, Incidence, and Mortality Rates","volume":"64","author":"Szepietowski","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jid.2024.03.043","article-title":"Genetic Study of Psoriasis Highlights Its Close Link with Socioeconomic Status and Affective Symptoms","volume":"144","author":"Sliz","year":"2024","journal-title":"J. Investig. Dermatol."},{"key":"ref_5","first-page":"1","article-title":"Update Aetiopathogenesis and Treatment of Psoriasis: A Literature Review","volume":"4","year":"2023","journal-title":"J. Dermatol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00251-021-01204-x","article-title":"Major Histocompatibility Complex (MHC) Associations with Diseases in Ethnic Groups of the Arabian Peninsula","volume":"73","author":"Mawart","year":"2021","journal-title":"Immunogenetics"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1111\/jdv.14266","article-title":"Combinations of Common Polymorphisms within GSTA1 and GSTT1 as a Risk Factor for Psoriasis in a Central European Population: A Case\u2013Control Study","volume":"31","author":"Hruska","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/jdv.20739","article-title":"Drug Survival of IL-23 and IL-17 Inhibitors versus Other Biologics for Psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register Cohort Study","volume":"39","author":"Yiu","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jdv.15920","article-title":"Systematic Review on Rapidity of Onset of Action for Interleukin-17 and Interleukin-23 Inhibitors for Psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Raam, L., Hartmane, I., Valiukevi\u010dien\u0117, S., Karamova, A.E., Telegdy, E., Botev, I., Marina, D., Rubant, S., Albuquerque, T., and Constantin, M.M. (2024). Disease Severity, Treatment Patterns, and Quality of Life in Patients with Moderate-to-Severe Psoriasis Routinely Managed with Systemic Treatment: Results of the CRYSTAL Observational Study in Central and Eastern European Countries. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1410540"},{"key":"ref_12","first-page":"875","article-title":"Psoriasis: Association of Interleukin-17 Gene Polymorphisms with Severity and Response to Treatment (Review)","volume":"18","author":"Roman","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Connell, W.T., Hong, J., and Liao, W. (2022). Genome-Wide Association Study of Ustekinumab Response in Psoriasis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.815121"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/jdv.18044","article-title":"Psoriasis and Metabolic Syndrome: Implications for the Management and Treatment of Psoriasis","volume":"36","author":"Wu","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ajhg.2015.10.019","article-title":"Genome-Wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture","volume":"97","author":"Stuart","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/bjd.15005","article-title":"Polymorphisms in CD84, IL12B and TNFAIP3 Are Associated with Response to Biologics in Patients with Psoriasis","volume":"176","author":"Coenen","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/jid.2013.170","article-title":"The IL23R A\/Gln381 Allele Promotes IL-23 Unresponsiveness in Human Memory T-Helper 17 Cells and Impairs Th17 Responses in Psoriasis Patients","volume":"133","author":"Villanova","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3892\/etm.2016.3066","article-title":"Candidate Gene Polymorphisms and Risk of Psoriasis: A Pilot Study","volume":"11","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Matei-Man, A.M., Gaal, I.O., Catana, A., Vesa, S., Senila, S., Candrea, E., Orasan, M., Puskas, A., Man, A.C., and Mocan, T. (2026). Genetic Association Study of IL23R and IL12B Polymorphisms with Psoriasis in a Romanian Population. Life, 16.","DOI":"10.3390\/life16040574"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/exd.14215","article-title":"Genome-Wide Association Analysis of Psoriasis Patients Treated with Anti-TNF Drugs","volume":"29","author":"Sabador","year":"2020","journal-title":"Exp. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/24755303241302070","article-title":"Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America","volume":"10","author":"Strober","year":"2025","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Zormpa, T., Thireou, T., Beloukas, A., Chaniotis, D., Golfinopoulou, R., Vlachakis, D., Eliopoulos, E., and Papageorgiou, L. (2025). The Genetic Background of Ankylosing Spondylitis Reveals a Distinct Overlap with Autoimmune Diseases: A Systematic Review. J. Clin. Med., 14.","DOI":"10.3390\/jcm14113677"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"jjaf061","DOI":"10.1093\/ecco-jcc\/jjaf061","article-title":"Gene-Environment Interactions in Inflammatory Bowel Disease: A Systematic Review of Human Epidemiologic Studies","volume":"19","author":"Bai","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity Management in Adults","volume":"330","author":"Schwartz","year":"2023","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2340\/00015555-1440","article-title":"IL-20, IL-21 and P40: Potential Biomarkers of Treatment Response for Ustekinumab","volume":"93","author":"Gedebjerg","year":"2013","journal-title":"Acta Derm. Venereol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00296-012-2637-4","article-title":"Meta-Analysis of IL12B Polymorphisms (Rs3212227, Rs6887695) with Psoriasis and Psoriatic Arthritis","volume":"33","author":"Zhu","year":"2013","journal-title":"Rheumatol. Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3109\/08820139.2013.810241","article-title":"Associations between Interleukin-23R and Interleukin-12B Polymorphisms and Psoriasis Susceptibility: A Meta-Analysis","volume":"42","author":"Lee","year":"2013","journal-title":"Immunol. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2217\/pgs-2017-0143","article-title":"Polymorphisms Associated with Adalimumab and Infliximab Response in Moderate-to-Severe Plaque Psoriasis","volume":"19","author":"Reolid","year":"2018","journal-title":"Pharmacogenomics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/tpj.2016.64","article-title":"New Polymorphisms Associated with Response to Anti-TNF Drugs in Patients with Moderate-to-Severe Plaque Psoriasis","volume":"18","author":"Cabaleiro","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Wang, C.Y., Wang, C.W., Chen, C.B., Chen, W.T., Chang, Y.C., Hui, R.C.Y., and Chung, W.H. (2023). Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087329"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-017-0322-9","article-title":"Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis","volume":"19","author":"Reolid","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/bjd.21677","article-title":"Biomarkers of Systemic Treatment Response in People with Psoriasis: A Scoping Review","volume":"187","author":"Corbett","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1038\/ncomms7916","article-title":"Genome-Wide Meta-Analysis Identifies Multiple Novel Associations and Ethnic Heterogeneity of Psoriasis Susceptibility","volume":"6","author":"Yin","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jaad.2019.12.038","article-title":"Comparison of Cumulative Clinical Benefits of Biologics for the Treatment of Psoriasis over 16 Weeks: Results from a Network Meta-Analysis","volume":"82","author":"Warren","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.19509","article-title":"A Head-to-Head Comparison of Ixekizumab vs. Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomized, Double-Blinded Trial*","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaci.2019.10.041","article-title":"Short-Term Transcriptional Response to IL-17 Receptor-A Antagonism in the Treatment of Psoriasis","volume":"145","author":"Tomalin","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/PTT.S356568","article-title":"Biologics Can Significantly Improve Dermatology Life Quality Index (DLQI) in Psoriatic Patients: A Systematic Review","volume":"12","author":"Rustemeyer","year":"2022","journal-title":"Psoriasis Targets Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamadermatol.2020.3617","article-title":"Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials","volume":"156","author":"Augustin","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A Head-to-Head Comparison of Ixekizumab vs. Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 12-Week Efficacy, Safety and Speed of Response from a Randomized, Double-Blinded Trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s12325-024-03034-1","article-title":"Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO)","volume":"42","author":"Khattri","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2147\/PTT.S534881","article-title":"Beyond Skin Clearance: Personalized Strategies for DLQI Improvement in Psoriasis -Insights from a Shanghai Prospective Cohort","volume":"15","author":"Ma","year":"2025","journal-title":"Psoriasis Targets Ther."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1041\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:46:38Z","timestamp":1779957998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["medicina62061041"],"URL":"https:\/\/doi.org\/10.3390\/medicina62061041","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}